Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AIMD

AIMD - Ainos, Inc. Stock Price, Fair Value and News

0.81USD0.00 (0.00%)Market Closed
Watchlist

Market Summary

USD0.810.00
Market Closed
0.00%

AIMD Stock Price

View Fullscreen

AIMD RSI Chart

AIMD Valuation

Market Cap

16.4M

Price/Earnings (Trailing)

-1.65

Price/Sales (Trailing)

4.73

EV/EBITDA

-5.27

Price/Free Cashflow

-3.65

AIMD Price/Sales (Trailing)

AIMD Profitability

Operating Margin

76.62%

EBT Margin

-216.81%

Return on Equity

-36.04%

Return on Assets

-29.47%

Free Cashflow Yield

-27.38%

AIMD Fundamentals

AIMD Revenue

Revenue (TTM)

3.5M

Rev. Growth (Yr)

-98.61%

Rev. Growth (Qtr)

-14.24%

AIMD Earnings

Earnings (TTM)

-10.0M

Earnings Growth (Yr)

61.95%

Earnings Growth (Qtr)

-26.65%

Breaking Down AIMD Revenue

Last 7 days

-9.8%

Last 30 days

-48.8%

Last 90 days

38.3%

How does AIMD drawdown profile look like?

AIMD Financial Health

Current Ratio

3.71

AIMD Investor Care

Shares Dilution (1Y)

1.40%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
2022679.6K1.1M2.5M3.5M
2021161.1K305.6K450.1K594.6K
202022.9K22.7K18.1K16.6K
201925.2K25.6K15.4K11.7K
2018307.5K57.3K72.2K77.7K
2017000250.9K
20160000
20150000
20140000
20130000
20120000
201118.5K31.8K45.1K58.4K
20100005.2K

Tracking the Latest Insider Buys and Sells of Ainos, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 16, 2024
sung meng lin
acquired
912
0.8693
1,050
chief financial officer
Feb 16, 2024
lin lawrence k
acquired
312
0.8693
360
e.v.p. of operations
Feb 16, 2024
tsai chun-hsien
acquired
22,688
0.8693
26,100
ceo, president, chairman
Feb 16, 2024
tsai chung-jung
acquired
14,082
0.8693
16,200
-
Feb 16, 2024
lee ting-chuan
acquired
12,517
0.8693
14,400
-
Jan 31, 2024
wei pao-sheng
acquired
1,378
0.94
1,466
-
Jan 31, 2024
tsai chung-yi
acquired
1,378
0.94
1,466
-
Jan 31, 2024
chiang yao-chung
acquired
1,378
0.94
1,466
-
Jan 31, 2024
chang wen-han
acquired
1,378
0.94
1,466
-
Nov 24, 2023
lin lawrence k
acquired
6,000
0.6
10,000
e.v.p. of operations

1–10 of 50

Which funds bought or sold AIMD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
STATE STREET CORP
sold off
-100
-18,724
-
-%
Feb 14, 2024
CVI Holdings, LLC
unchanged
-
-9,628
17,325
0.04%
Feb 14, 2024
BOOTHBAY FUND MANAGEMENT, LLC
unchanged
-
35,750
51,250
-%
Feb 14, 2024
Anson Funds Management LP
reduced
-80.00
-10,500
20,500
-%
Feb 14, 2024
Hudson Bay Capital Management LP
reduced
-60.28
-18,441
6,323
-%
Feb 14, 2024
CITADEL ADVISORS LLC
sold off
-100
-8,675
-
-%
Feb 14, 2024
CITADEL ADVISORS LLC
added
42.67
-868
9,594
-%
Feb 13, 2024
ARMISTICE CAPITAL, LLC
unchanged
-
-7,128
1,050
-%
Feb 13, 2024
Tower Research Capital LLC (TRC)
sold off
-100
-5,946
-
-%
Feb 13, 2024
Tower Research Capital LLC (TRC)
new
-
3,807
3,807
-%

1–10 of 27

Are Funds Buying or Selling AIMD?

Are funds buying AIMD calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AIMD
No. of Funds

Unveiling Ainos, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 29, 2024
ainos inc
62.05%
2,938,487
SC 13D/A

Recent SEC filings of Ainos, Inc.

View All Filings
Date Filed Form Type Document
Feb 20, 2024
4
Insider Trading
Feb 20, 2024
4
Insider Trading
Feb 20, 2024
4
Insider Trading
Feb 20, 2024
4
Insider Trading
Feb 20, 2024
4
Insider Trading
Feb 15, 2024
10-Q/A
Quarterly Report
Feb 05, 2024
8-K
Current Report
Feb 02, 2024
4
Insider Trading
Feb 02, 2024
4
Insider Trading
Feb 02, 2024
4
Insider Trading

Peers (Alternatives to Ainos, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
207.1B
40.1B
0.08% 5.41%
36.19
5.16
-8.12% -17.45%
70.3B
19.5B
1.90% -2.48%
56
3.61
4.02% -22.04%
24.2B
3.8B
13.67% -2.23%
66.83
6.37
-1.48% -28.97%
21.3B
14.9B
3.05% 1.38%
8.03
1.43
2.01% 209.17%
MID-CAP
10.0B
12.7B
2.56% -12.12%
22.51
0.79
0.68% -30.25%
9.9B
2.7B
6.89% -27.73%
-15.59
3.72
-4.68% 82.43%
9.3B
3.5B
8.76% 25.90%
32.84
2.68
4.97% 18.89%
7.1B
3.9B
-8.15% -6.44%
-32.48
1.81
-2.62% 73.16%
3.5B
342.6M
-1.40% 20.18%
-287.71
10.08
42.19% 84.12%
2.6B
6.6B
-4.32% -4.67%
13.13
0.4
2.61% 0.52%
SMALL-CAP
1.0B
3.1B
8.08% -63.68%
-2.41
0.33
7.95% -543.98%
363.5M
163.3M
8.18% -20.52%
-14.79
2.23
7.14% -56.09%
238.7M
329.5M
3.17% -52.24%
-16.91
0.72
0.49% 64.22%
74.1M
50.3M
4.50% -30.54%
-4.89
1.47
3.23% 20.81%
4.5M
3.7M
-15.66% 215.09%
-0.37
1.19
5.77% 8.23%

Ainos, Inc. News

Latest updates
InvestorsObserver12 Feb 202408:00 am
Seeking Alpha24 Jan 202408:00 am
InvestorsObserver24 Jan 202408:00 am
InvestorPlace05 Jan 202408:00 am
InvestorsObserver05 Jan 202408:00 am
InvestorsObserver26 Dec 202308:00 am
InvestorPlace7 months ago

Ainos, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-14.2%24.0029.005331,0381,75863787.0026.00363203102687*192*484*15.002.005.00606*4.006.0015.00
Cost Of Revenue57.4%88.0056.001015781,17631941.0010.0010470.001.0056*123*292*11.002.003.00563*3.004.0017.00
Gross Profit-132.5%-63.38-27.26-51.6846058231846.0017.00259133872*631*69*192*4.00140*1.0043*1.002.00-1.88
Operating Expenses14.1%2,6122,2892,4612,5868,4042,2622,1292,3121,443-860523824321301-380370367455392488307
  S&GA Expenses45.9%9026187627886,569627552178796860523824321300-380370367405389455307
  R&D Expenses2.3%1,7101,6711,6991,7991,8351,6351,5771,274647----389*---50.002.00--
EBITDA Margin0.0%-0.77*-0.77*-0.77*-0.78*-1.24*0.99*3.39*3.88*0.05*0.09*0.16*0.86*---------
Interest Expenses-44.00--16.0010.003.0017.009.00-1.713.0012.005.003.001.00-176*524*134*69*274*1.00
Income Taxes----------------------
Earnings Before Taxes-26.6%-2,975-2,349---7,821-1,954-16.832,162-1,160-749-11.90--323-301-------
EBT Margin0%-2.17*-2.17*-2.17*-2.17*-3.04*-0.87*0.35*0.40*-0.02*-0.03*-0.06*-0.62*---------
Net Income-26.6%-2,975-2,349-2,520-2,131-7,821-1,954-2,099-1,444-1,160-749-534-448-323-301-376-370-366-453-391-486-310
Net Income Margin32.7%-2.83*-4.21*-4.10*-3.98*-5.31*-5.98*-8.03*-6.54*-6.43*-6.73*-9.98*-87.58*-75.65*--------
Free Cashflow33.3%-815-1,223-1,499-564-927-375-1,525-78319,432169-211-254---------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-0.5%33,86034,04636,70837,10939,08240,41340,73640,82219,99420,62213,8497,0753013374795976929451,2261,4641,517
  Current Assets42.1%3,0402,1403,6332,8463,6683,6993,0232,21888586942.0076.001581923324455527981,0711,3031,196
    Cash Equivalents74.2%2,3711,3611,1461,8532,4171,7541,8711,7517076079.0022.0084.001732904094837231,0461,2771,143
  Inventory-58.8%217528572595-------3.003.004.004.004.006.0010.009.00--
  Net PPE-8.5%1,1611,2691,3151,3761,3511,5031,4201,18840.0023.003.003.004.004.004.005.002.006.0011.0014.0019.00
Liabilities69.2%6,1793,6514,3702,4812,65634,40732,65430,6252,8572,4171,5001,0991,078881913753613705674734707
  Current Liabilities-26.4%8191,1141,8672,4732,6436,9885,73030,5952,8222,3761,5001,0991,078881913753613705674734707
Shareholder's Equity-8.9%27,68130,39532,33834,62836,4266,0068,08310,19717,13618,2065,0555,3544,5864,2994,3084,20879.003,876552730810
  Retained Earnings-10.3%-31,961-28,985-26,636-24,115-21,984-14,162-12,208-10,108-8,664-7,504-6,754-6,220-5,771-5,448-5,146-4,769-4,399-4,033-3,579-3,188-2,702
  Additional Paid-In Capital0.6%59,76459,424-58,96558,74558,49218,94320,24720,20424,36924,2875,0554,9614,5864,4954,3084,2084,0763,8763,7363,5273,139
Shares Outstanding1.4%20,29320,01220,01220,01219,4789,6259,6259,6259,4969,4852,8042,8042,708--------
Float----3,143---18,258---3,792---9,139-----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations35.4%-743-1,151-1,427-600-791-239-1,389-680-526169-211-254--129-115-130-240-322-216-311-307
  Share Based Compensation136.8%3251372212596,07643.0043.00-21819.0094.0094.00----------
Cashflow From Investing-3889.2%-46.271.00-72.4835.00-240-288-135-137-20.06-23.28--5.35-621*---11.06-406*1*-1.64-62.9258.00
Cashflow From Financing32.2%1,8381,391795-19.551,6515551,6451,86464045219935.0075.00-92.8410367.00---12.50450-

AIMD Income Statement

2023-09-30
Condensed Statements of Operations (Unaudited) - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Condensed Statements of Operations (Unaudited)    
Revenues (including amounts of related party of $21,224 and $1,506,225 for the three months ended September 30, 2023 and 2022, and $33,765 and $1,988,150 for the nine months ended September 30, 2023 and 2022, respectively)$ 24,489$ 1,757,774$ 102,208$ 2,481,602
Cost of revenues (including amounts of related party of $39,523 and $732,765 for the three months ended September 30, 2023 and 2022, and $86,158 and $1,603,169 for the nine months ended September 30, 2023 and 2022, respectively)(87,873)(1,176,032)(244,538)(1,536,074)
Gross (loss) profit(63,384)581,742(142,330)945,528
Operating expenses:    
Research and development expenses (including amounts of related party of $135,606 and $115,912 for the three months ended September 30, 2023 and 2022, and $287,802 and $490,082 for the nine months ended September 30, 2023 and 2022, respectively)1,710,2651,834,7865,080,3355,047,096
Selling, general and administrative expenses902,0176,569,2272,282,6317,748,060
Total operating expenses2,612,2828,404,0137,362,96612,795,156
Loss from operations(2,675,666)(7,822,271)(7,505,296)(11,849,628)
Interest expense(44,267)(9,821)(93,852)(45,304)
Other income, net5,05410,33614,06719,250
Issuance cost of convertible note measured at fair value(260,967)0(260,967)0
Total non-operating (expenses) income, net(300,180)515(340,752)(26,054)
Net loss before income taxes(2,975,846)(7,821,756)(7,846,048)(11,875,682)
Provision for income taxes0000
Net loss$ (2,975,846)$ (7,821,756)$ (7,846,048)$ (11,875,682)
Net loss per common share - basic and diluted$ (0.15)$ (0.51)$ (0.39)$ (1.03)
Weighted-average shares used in computing net loss per common share-basic and diluted20,292,62415,301,39620,134,34011,538,013

AIMD Balance Sheet

2023-09-30
Condensed Balance Sheets - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 2,370,963$ 1,853,362
Accounts receivable (including amounts of related party of nil and $177,595 as of September 30, 2023 and December 31,2022, respectively)162201,546
Inventory, net217,328595,222
Other current assets451,698195,787
Total current assets3,040,1512,845,917
Intangible assets, net29,422,93732,806,738
Property and equipment, net1,161,4821,375,676
Other assets235,21580,683
Total assets33,859,78537,109,014
Contract liabilities111,7170
Convertible notes payable, related party0376,526
Other notes payable, related party42,000884,000
Accrued expenses and others current liabilities665,7681,212,386
Total current liabilities819,4852,472,912
Convertible notes payable - noncurrent (including amounts of related party of $2,000,000 and nil as of September 30, 2023 and December 31, 2022, respectively)3,000,0000
Senior secured convertible notes measured at fair value2,000,0000
Other notes payable, related party - noncurrent270,0000
Other long-term liabilities89,3338,096
Total liabilities6,178,8182,481,008
Stockholders' equity:  
Common stock, $0.01 par value; 300,000,000 shares authorized as of September 30, 2023 and December 31, 2022, 20,292,624 and 20,011,602 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively202,926200,116
Additional paid-in capital59,763,98758,745,149
Accumulated deficit(31,961,654)(24,115,606)
Translation adjustment(324,292)(201,653)
Total stockholders' equity27,680,96734,628,006
Total liabilities and stockholders' equity$ 33,859,785$ 37,109,014
AIMD
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.
 CEO
 WEBSITEwww.ainos.com
 EMPLOYEES43

Ainos, Inc. Frequently Asked Questions


What is the ticker symbol for Ainos, Inc.? What does AIMD stand for in stocks?

AIMD is the stock ticker symbol of Ainos, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ainos, Inc. (AIMD)?

As of Thu Feb 22 2024, market cap of Ainos, Inc. is 16.44 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AIMD stock?

You can check AIMD's fair value in chart for subscribers.

What is the fair value of AIMD stock?

You can check AIMD's fair value in chart for subscribers. The fair value of Ainos, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ainos, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AIMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ainos, Inc. a good stock to buy?

The fair value guage provides a quick view whether AIMD is over valued or under valued. Whether Ainos, Inc. is cheap or expensive depends on the assumptions which impact Ainos, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AIMD.

What is Ainos, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, AIMD's PE ratio (Price to Earnings) is -1.65 and Price to Sales (PS) ratio is 4.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AIMD PE ratio will change depending on the future growth rate expectations of investors.